Sounds good to me!
Recently, Quest Diagnostics (DGX) introduced its latest lab-developed genetic test for the delivery of personalized opioid pain-relieving treatment. Quest Diagnostics developed this test using Transgenomic, Inc.’s (TBIO) gene variant through a non-exclusive licensing agreement with the latter. However, additional terms of the deal were not disclosed.
With the rollout of this test, Quest will become the first clinical lab with assays for variants in all cytochrome P450 (CYP450) genes that influence the CYP450 enzyme system. We also note that opioids include oxycodone and methadone, and are very effective pain-alleviating medications. The metabolism of opioids and other medications are affected by the CYP450 enzyme system.
According to Quest Diagnostics, this genetic testing will prove effective in predicting the rate of opioid drug metabolism. It will also help the physicians to decide on adjustment of dosages or usage of other therapies, reducing the likelihood of drug toxicity, drug interactions, and other adverse outcomes.